Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology

Overview of attention for article published in Stem Cell Research & Therapy, March 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 21 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 12,397 followers.

Li, L., Yi, H., Liu, Z. et al. Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology. Stem Cell Res Ther 13, 102 (2022). https://t.co/O9sXCR3hxi

09 Mar 2022

Reply Repost Favourite

Genetic correction of concurrent alpha- and beta-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology https://t.co/Bjz6vsSvQz

08 Mar 2022

Reply Repost Favourite

New article: Genetic correction of concurrent alpha- and beta-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology https://t.co/gi2UWoVSP4 #BT #thalassemia #hematology https://t.co/K5l8k8gctx

08 Mar 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.